Emerging Therapy Critiques
Therapies Friday, September 27th, 2013AHA Stroke: August 27, 2013
Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, with 30-day mortality rates of ≈40% and significant morbidity among survivors.1 Progress has proven difficult for this disease state. Unlike ischemic stroke, where incidence seems to be declining in high-wealth countries,2and subarachnoid hemorrhage, where case fatality has improved,3 there is little evidence that ICH has become less common or less morbid.1
Fortunately, many clinicians and researchers have been unwilling to accept a nihilistic attitude toward parenchymal brain hemorrhage. In the past decade, large trials have tested a variety of treatment approaches for ICH, including neuroprotection,4 blood pressure control,5 hemostatic therapy,6 and surgery.7 Recently, results of the second International Surgical Trial in Intracerebral Hemorrhage (STICH II) were published. Read More